Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector.
Lumpy skin disease virus (LSDV), a capripoxvirus with a host range limited to ruminants, was evaluated as a replication-deficient vaccine vector for use in non-ruminant hosts. By using the rabies virus glycoprotein (RG) as a model antigen, it was demonstrated that recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) was able to express RG in both permissive (ruminant) and non-permissive (non-ruminant) cells. The recombinant LSDV, however, replicated to maturity only in permissive but not in non-permissive cells. Recombinant LSDV-RG was assessed for its ability to generate immunity against RG in non-ruminant hosts (rabbits and mice). Rabbits inoculated with rLSDV-RG produced rabies virus (RV) neutralizing antibodies at levels twofold higher than those reported by the WHO to be protective. BALB/c mice immunized with rLSDV-RG elicited levels of RV-specific cellular immunity (T-cell proliferation) comparable with those of mice immunized with a commercial inactivated rabies vaccine (Verorab; Pasteur Merieux). Most importantly, mice immunized with rLSDV-RG were protected from an aggressive intracranial rabies virus challenge.
Aspden
Kate
K
Division of Medical Virology, Department of Clinical Laboratory Science & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa.
Passmore
Jo-Ann
JA
Division of Medical Virology, Department of Clinical Laboratory Science & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa.
Tiedt
Friedrich
F
Division of Medical Virology, Department of Clinical Laboratory Science & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa.
Williamson
Anna-Lise
AL
National Health Laboratory Service, University of Cape Town, Observatory 7925, Cape Town, South Africa.|Division of Medical Virology, Department of Clinical Laboratory Science & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa.
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral; D018151:Capripoxvirus / Q000145:classification; D002417:Cattle; D002460:Cell Line; D005822:Genetic Vectors; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology; D007114:Immunization; D008167:Lumpy skin disease virus / Q000235:genetics* / Q000502:physiology; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D011818:Rabies / Q000517:prevention & control; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D011995:Recombination, Genetic; D013601:T-Lymphocytes / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014779:Virus Replication
D000914:Antibodies, Viral; D000956:Antigens, Viral; D006023:Glycoproteins; D011819:Rabies Vaccines; D014759:Viral Envelope Proteins; C064951:glycoprotein G, Rabies virus